Critical Analysis: Abivax (NASDAQ:ABVX) and SELLAS Life Sciences Group (NASDAQ:SLS)

SELLAS Life Sciences Group (NASDAQ:SLS) and Abivax (NASDAQ:ABVX) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, institutional ownership, risk, profitability and earnings.

Analyst Ratings

This is a summary of current ratings for SELLAS Life Sciences Group and Abivax, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SELLAS Life Sciences Group	1	0	2	0	2.33
Abivax	1	1	14	0	2.81

SELLAS Life Sciences Group currently has a consensus price target of $10.00, indicating a potential downside of 25.35%. Abivax has a consensus price target of $148.54, indicating a potential upside of 10.03%. Given Abivax’s stronger consensus rating and higher possible upside, analysts plainly believe Abivax is more favorable than SELLAS Life Sciences Group.

Profitability

This table compares SELLAS Life Sciences Group and Abivax’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
SELLAS Life Sciences Group	N/A	-47.12%	-42.63%
Abivax	N/A	-99.02%	-70.26%

Volatility and Risk

SELLAS Life Sciences Group has a beta of 2.42, meaning that its share price is 142% more volatile than the S&P 500. Comparatively, Abivax has a beta of 0.87, meaning that its share price is 13% less volatile than the S&P 500.

Institutional & Insider Ownership

17.4% of SELLAS Life Sciences Group shares are owned by institutional investors. Comparatively, 47.9% of Abivax shares are owned by institutional investors. 1.3% of SELLAS Life Sciences Group shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares SELLAS Life Sciences Group and Abivax”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SELLAS Life Sciences Group	N/A	N/A	-$26.86 million	($0.23)	-58.24
Abivax	N/A	N/A	-$380.27 million	($5.21)	-25.91

SELLAS Life Sciences Group is trading at a lower price-to-earnings ratio than Abivax, indicating that it is currently the more affordable of the two stocks.

Summary

SELLAS Life Sciences Group beats Abivax on 6 of the 11 factors compared between the two stocks.

About SELLAS Life Sciences Group

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company’s lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.

About Abivax

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.